Production starts at COVID-19 test equipment plant in NETDA
A new plant being operated by MEDsan Pharmaceutical Technology (Nantong) Co Ltd, based in the Nantong Economic & Technological Development Area, or NETDA – located in Nantong city, in East China's Jiangsu province – began production on Dec 29, according to local media reports.
When it fully ramps up, the plant on a daily basis is projected to produce more than 1.5 million detection reagents and 500 sets of testing equipment for the novel coronavirus.
The MEDsan Pharmaceutical plant, with a total investment of 500 million yuan ($78.43 million), was funded and established by Nantong Egens Biotechnology Co Ltd – a stock exchange-listed company that is resident in the NETDA – engaged in ventures to help prevent and control COVID-19.
The new plant has a floor space covering about 22,000 square meters. It is mainly engaged in the R&D, production and sales of novel coronavirus detection-related medical products.
The core products are high-tech items designed to provide epidemic prevention support for Europe, Asia, South America, Africa and other counties and regions in the world.
The newly opened MEDsan Pharmaceutical plant can produce more than 1.5 million detection reagents daily and 500 sets of testing equipment for the coronavirus. [Photo provided to NETDA]
A technician at MEDsan Pharmaceutical checks the production line. [Photo provided to NETDA]
A member of staff works on the production line. [Photo provided to NETDA]
